Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
2.

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 Aug;28(8):2255. doi: 10.1007/s11136-019-02204-x.

3.

Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 Aug;28(8):2247-2254. doi: 10.1007/s11136-019-02148-2. Epub 2019 Mar 23. Erratum in: Qual Life Res. 2019 May 21;:.

4.

Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study.

Howard JFB, Rokx C, Smit C, Wit FWNM, Pieterman ED, Meijer K, Rijnders B, Bierman WFW, Tichelaar YIGV; ATHENA observational HIV cohort investigators.

Lancet HIV. 2019 Mar;6(3):e173-e181. doi: 10.1016/S2352-3018(18)30333-3. Epub 2019 Feb 15. Erratum in: Lancet HIV. 2019 Apr 3;:.

PMID:
30777727
5.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.

Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.

6.

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF Jr, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK.

Muscle Nerve. 2019 Apr;59(4):404-410. doi: 10.1002/mus.26404. Epub 2019 Jan 14.

PMID:
30575980
7.

Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Li Y, Guptill JT, Russo MA, Massey JM, Juel VC, Hobson-Webb LD, Howard JF, Chopra M, Liu W, Yi JS.

Exp Neurol. 2019 Feb;312:43-50. doi: 10.1016/j.expneurol.2018.11.006. Epub 2018 Nov 22.

PMID:
30472069
8.

Circulating microRNA plasma profile in MuSK+ myasthenia gravis.

Sabre L, Guptill JT, Russo M, Juel VC, Massey JM, Howard JF Jr, Hobson-Webb LD, Punga AR.

J Neuroimmunol. 2018 Dec 15;325:87-91. doi: 10.1016/j.jneuroim.2018.10.003. Epub 2018 Oct 6.

PMID:
30316681
9.

Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment.

Allard DE, Wang Y, Li JJ, Conley B, Xu EW, Sailer D, Kimpston C, Notini R, Smith CJ, Koseoglu E, Starmer J, Zeng XL, Howard JF Jr, Hoke A, Scherer SS, Su MA.

J Clin Invest. 2018 Oct 1;128(10):4727-4741. doi: 10.1172/JCI99308. Epub 2018 Sep 17.

10.

In Vivo Viscoelastic Response (VisR) Ultrasound for Characterizing Mechanical Anisotropy in Lower-Limb Skeletal Muscles of Boys with and without Duchenne Muscular Dystrophy.

Moore CJ, Caughey MC, Meyer DO, Emmett R, Jacobs C, Chopra M, Howard JF Jr, Gallippi CM.

Ultrasound Med Biol. 2018 Dec;44(12):2519-2530. doi: 10.1016/j.ultrasmedbio.2018.07.004. Epub 2018 Aug 31.

PMID:
30174231
11.

A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.

Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Hirtz D, Lochmuller H, Straub V, Ciafaloni E, Shieh PB, Spinty S, Childs AM, Manzur AY, Morandi L, Butterfield RJ, Horrocks I, Roper H, Flanigan KM, Kuntz NL, Mah JK, Morrison L, Darras BT, von der Hagen M, Schara U, Wilichowski E, Mongini T, McDonald CM, Vita G, Barohn RJ, Finkel RS, Wicklund M, McMillan HJ Jr, Hughes I, Pegoraro E, Bryan Burnette W, Howard JF, Thangarajh M, Campbell C, Griggs RC, Bushby K, Guglieri M.

Trials. 2018 May 10;19(1):291. doi: 10.1186/s13063-018-2645-0. Review.

12.
13.

Distinct representation of muscle weakness in QMG and MG-ADL - Authors' reply.

Howard JF Jr, O'Brien F, Wang JJ.

Lancet Neurol. 2018 Mar;17(3):205-206. doi: 10.1016/S1474-4422(18)30036-X. No abstract available.

PMID:
29452680
14.

IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration.

Smith CJ, Allard DE, Wang Y, Howard JF Jr, Montgomery SA, Su MA.

J Immunol. 2018 Mar 1;200(5):1580-1592. doi: 10.4049/jimmunol.1701280. Epub 2018 Jan 24.

15.

Myasthenia gravis: the role of complement at the neuromuscular junction.

Howard JF Jr.

Ann N Y Acad Sci. 2018 Jan;1412(1):113-128. doi: 10.1111/nyas.13522. Epub 2017 Dec 21. Review.

PMID:
29266249
16.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
17.

Learning from the past: reflections on recently completed myasthenia gravis trials.

Benatar M, Howard JF Jr, Barohn R, Wolfe GI, Cutter G.

Ann N Y Acad Sci. 2018 Jan;1412(1):5-13. doi: 10.1111/nyas.13501. Epub 2017 Oct 24.

18.

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.

Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM.

Neurology. 2017 Sep 5;89(10):1069-1077. doi: 10.1212/WNL.0000000000004341. Epub 2017 Aug 11.

PMID:
28801338
19.

Brachial Plexus Injury in a 6-Year-Old Boy with 100% Displaced Proximal Humeral Metaphyseal Fracture: A Case Presentation.

Jovanovich EN, Howard JF Jr.

PM R. 2017 Dec;9(12):1294-1298. doi: 10.1016/j.pmrj.2017.05.009. Epub 2017 Jun 9.

PMID:
28606839
20.

The Relationship between Trans-Lesional Conduction, Motor Neuron Pool Excitability, and Motor Function in Dogs with Incomplete Recovery from Severe Spinal Cord Injury.

Lewis MJ, Howard JF Jr, Olby NJ.

J Neurotrauma. 2017 Nov 1;34(21):2994-3002. doi: 10.1089/neu.2017.5012. Epub 2017 Jun 16.

21.

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs AM, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC.

Contemp Clin Trials. 2017 Jul;58:34-39. doi: 10.1016/j.cct.2017.04.008. Epub 2017 Apr 24.

22.

Seronegative myasthenia gravis associated with malignant thymoma.

Richards J, Howard JF Jr.

Neuromuscul Disord. 2017 May;27(5):417-418. doi: 10.1016/j.nmd.2017.01.023. Epub 2017 Feb 2.

PMID:
28238572
23.

Marked clinical and jitter improvement after eculizumab in refractory myasthenia.

Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O'Brien F, Wang JJ, Howard JF Jr.

Muscle Nerve. 2017 Sep;56(3):E16-E18. doi: 10.1002/mus.25620. Epub 2017 Jun 5. No abstract available.

PMID:
28214342
24.

QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.

Howard JF Jr, Freimer M, O'Brien F, Wang JJ, Collins SR, Kissel JT; MG (Phase2) Study Group.

Muscle Nerve. 2017 Aug;56(2):328-330. doi: 10.1002/mus.25529. Epub 2017 Feb 25.

PMID:
28010051
25.

Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.

Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, Esfandiari E, Buchanan T, Smith B, Atherfold P, Jones E, Howard JF Jr.

Autoimmunity. 2016 Nov;49(7):472-479. Epub 2016 Aug 11.

26.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

27.

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI.

Muscle Nerve. 2016 Feb;53(2):165-8. doi: 10.1002/mus.25009. Epub 2015 Dec 21. No abstract available.

PMID:
26662952
28.

Late-onset Becker muscular dystrophy: Refining the clinical features and electrophysiological findings.

Beltran Papsdorf T, Howard JF Jr, Chahin N.

Muscle Nerve. 2015 Nov;52(5):885-7. doi: 10.1002/mus.24773. Epub 2015 Sep 10.

PMID:
26179421
29.

High-Pressure Transvenous Perfusion of the Upper Extremity in Human Muscular Dystrophy: A Safety Study with 0.9% Saline.

Fan Z, Kocis K, Valley R, Howard JF Jr, Chopra M, Chen Y, An H, Lin W, Muenzer J, Powers W.

Hum Gene Ther. 2015 Sep;26(9):614-21. doi: 10.1089/hum.2015.023. Epub 2015 Jul 30.

30.

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

31.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, ChiĆ² A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

32.

The effect of sacral neuromodulation on pudendal nerve function and female sexual function.

Parnell BA, Howard JF Jr, Geller EJ.

Neurourol Urodyn. 2015 Jun;34(5):456-60. doi: 10.1002/nau.22579. Epub 2014 Feb 24.

PMID:
24615871
33.

Pearls & Oy-sters: clues to the diagnosis of adult-onset acid maltase deficiency.

Beltran Papsdorf TB, Howard JF Jr, Chahin N.

Neurology. 2014 Mar 4;82(9):e73-5. doi: 10.1212/WNL.0000000000000163. No abstract available.

34.

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.

Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group.

Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30.

PMID:
23512355
35.

Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency.

Zeng XL, Nagavalli A, Smith CJ, Howard JF, Su MA.

J Immunol. 2013 Apr 15;190(8):3895-904. doi: 10.4049/jimmunol.1203001. Epub 2013 Mar 13.

36.

Electrodiagnosis of disorders of neuromuscular transmission.

Howard JF Jr.

Phys Med Rehabil Clin N Am. 2013 Feb;24(1):169-92. doi: 10.1016/j.pmr.2012.08.013. Epub 2012 Oct 26. Review.

PMID:
23177038
37.

The paradox of muscle hypertrophy in muscular dystrophy.

Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, Wang J, Fan Z, Howard JF Jr, Schatzberg SJ, Dow JL, Grange RW, Styner MA, Hoffman EP, Wagner KR.

Phys Med Rehabil Clin N Am. 2012 Feb;23(1):149-72, xii. doi: 10.1016/j.pmr.2011.11.014. Review.

38.

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X, Hoffman EP.

Mamm Genome. 2012 Feb;23(1-2):85-108. doi: 10.1007/s00335-011-9382-y. Epub 2012 Jan 5. Review.

39.

Idiopathic intracranial hypertension in a child with Duchenne muscular dystrophy.

Weig SG, Zinn MM, Howard JF Jr.

Pediatr Neurol. 2011 Dec;45(6):406-8. doi: 10.1016/j.pediatrneurol.2011.09.013.

PMID:
22115006
40.

Safety and feasibility of high-pressure transvenous limb perfusion with 0.9% saline in human muscular dystrophy.

Fan Z, Kocis K, Valley R, Howard JF, Chopra M, An H, Lin W, Muenzer J, Powers W.

Mol Ther. 2012 Feb;20(2):456-61. doi: 10.1038/mt.2011.137. Epub 2011 Jul 19.

41.

Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.

Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, Wang B, Qiao C, Howard JF Jr, Xiao X.

Mol Ther. 2010 Aug;18(8):1501-8. doi: 10.1038/mt.2010.94. Epub 2010 Jun 1.

42.

Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.

Donofrio PD, Berger A, Brannagan TH 3rd, Bromberg MB, Howard JF, Latov N, Quick A, Tandan R.

Muscle Nerve. 2009 Nov;40(5):890-900. doi: 10.1002/mus.21433. Review.

PMID:
19768755
43.

Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

PM R. 2009 Jan;1(1):14-22. doi: 10.1016/j.pmrj.2008.11.011. Review.

PMID:
19627868
44.

Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

PM R. 2009 Jan;1(1):5-13. doi: 10.1016/j.pmrj.2008.11.010. Review.

PMID:
19627867
45.

Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review).

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

Muscle Nerve. 2009 Jan;39(1):106-15. doi: 10.1002/mus.21227. Review.

PMID:
19086069
46.

Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review).

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann D, Howard JF, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation.

Muscle Nerve. 2009 Jan;39(1):116-25. doi: 10.1002/mus.21226. Review.

PMID:
19086068
47.

Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF Jr, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology.

Neurology. 2009 Jan 13;72(2):177-84. doi: 10.1212/01.wnl.0000336345.70511.0f. Epub 2008 Dec 3. Review.

48.

Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.

England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, Asbury AK, Szigeti K, Lupski JR, Latov N, Lewis RA, Low PA, Fisher MA, Herrmann DN, Howard JF Jr, Lauria G, Miller RG, Polydefkis M, Sumner AJ; American Academy of Neurology.

Neurology. 2009 Jan 13;72(2):185-92. doi: 10.1212/01.wnl.0000336370.51010.a1. Epub 2008 Dec 3. Review.

PMID:
19056666
49.

Chapter 12 Neurotoxicology of neuromuscular transmission.

Howard JF Jr, Sanders DB.

Handb Clin Neurol. 2008;91:369-400. doi: 10.1016/S0072-9752(07)01512-6. Review. No abstract available.

PMID:
18631850
50.

Myokymia and neuromyotonia in a cat.

Galano HR, Olby NJ, Howard JF Jr, Shelton GD.

J Am Vet Med Assoc. 2005 Nov 15;227(10):1608-12, 1591.

PMID:
16313038

Supplemental Content

Loading ...
Support Center